What is the 13F Pro Quality Score for SRZN?

13F Pro ranks Surrozen, Inc./DE (SRZN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SRZN's current score at https://13fpro.ai/research/SRZN (free sign-up required for the full ranking).

Which hedge funds own the most SRZN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SRZN include Column Group, TCG Crossover Management,, Boxer Capital Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SRZN as soon as new 13F filings post.

Where does 13F Pro source SRZN data?

All Surrozen, Inc./DE fundamentals and ownership data come directly from SEC EDGAR. Surrozen, Inc./DE files with the SEC under CIK 1824893. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SRZN in?

Surrozen, Inc./DE (SRZN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SRZN research updated on 13F Pro?

SRZN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Surrozen, Inc./DE(SRZN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1824893 SRZN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $12.5M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SRZN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Surrozen, Inc./DE (SRZN), a Healthcare sector company. SRZN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $12.5m in revenue. Based on the latest XBRL financial filings (Q1 2026), Surrozen, Inc./DE reports quarterly revenue of $5.0M, net income of $-127.5M, free cash flow of $-12.6M. Top institutional holders of SRZN by reported 13-F value include Column Group, TCG Crossover Management,, Boxer Capital Management,, based on the most recent SEC filings. SRZN trades on the Nasdaq exchange and files with the SEC under CIK 1824893. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SRZN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Surrozen, Inc./DE directly from SEC EDGAR.

Revenue

Q1 2026

$5.0M

Net Income

Q1 2026

$-127.5M

Free Cash Flow

Q1 2026

$-12.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-67.4% YoY

$3.5MFY 2025

FY22 $12.5MFY23 $0.00FY24 $10.7MFY25 $3.5M

Net Income

-280.8% YoY

$-242.0MFY 2025

FY22 $-36.0MFY23 $-43.0MFY24 $-63.6MFY25 $-242.0M

Operating Income

-64.8% YoY

$-42.1MFY 2025

FY22 $-44.3MFY23 $-45.8MFY24 $-25.5MFY25 $-42.1M

EPS (Diluted)

-49.4% YoY

$-32.37FY 2025

FY22 $-1.04FY23 $-21.33FY24 $-21.67FY25 $-32.37

Total Assets

+103.7% YoY

$98.7MFY 2025

FY22 $89.4MFY23 $46.1MFY24 $48.5MFY25 $98.7M

Op. Cash Flow

-71.6% YoY

$-30.2MFY 2025

FY22 $-44.1MFY23 $-40.4MFY24 $-17.6MFY25 $-30.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$3.5M -67.4%	$10.7M	$0.00 -100.0%	$12.5M	$0.00	—
Net Income	$-242.0M -280.8%	$-63.6M -47.7%	$-43.0M -19.5%	$-36.0M +34.1%	$-54.6M	—
Operating Income	$-42.1M -64.8%	$-25.5M +44.2%	$-45.8M -3.2%	$-44.3M +18.5%	$-54.4M	—
EPS (Diluted)	$-32.37 -49.4%	$-21.67 -1.6%	$-21.33 -1956.3%	$-1.04 -604.2%	$-0.15	—
Total Assets	$98.7M +103.7%	$48.5M +5.2%	$46.1M -48.5%	$89.4M -34.8%	$137.2M	—
Operating Cash Flow	$-30.2M -71.6%	$-17.6M +56.3%	$-40.4M +8.6%	$-44.1M +9.6%	$-48.8M	—

AI Insight: SRZN Financial Trends

Surrozen's equity turned deeply negative at -$278M in Q1 2026 as cumulative net losses accelerate, raising acute balance-sheet solvency concerns.

• Equity collapsed from $47M in Q2 2025 to -$278M in Q1 2026 — a $325M swing in three quarters.

• Net losses surged from -$72M in Q3 2025 to -$183M in Q4 2025 and -$128M in Q1 2026, signaling accelerating cash burn.

• Revenue ticked up to $5M in Q1 2026 from a flat $1M across the prior five quarters — only modest top-line progress.

• Operating cash flow deteriorated to -$12M in Q1 2026, the worst level in the dataset, with no debt reported to offset losses.

⚠ Deeply negative equity of -$278M with no reported debt raises urgent questions about funding runway and potential dilution or insolvency.

⚠ The Q2 2025 net income spike of $40M appears one-time; its reversal drove the subsequent loss acceleration — nature of that item warrants scrutiny.

⚠ Operating losses widened steadily from -$9M in Q2 2024 to -$13M in Q4 2025; monitor whether Q1 2026's -$10M signals any stabilization.

AI Insight: SRZN Ratio Trends

Data too sparse to establish reliable trends — only two isolated ratio readings available across nine reported periods.

• ROA of -94.0% in Q1 2025 signals deeply negative asset returns, consistent with a pre-revenue or early-clinical-stage company.

• ROIC swung from 87.0% in Q3 2024 to -76.5% in Q2 2025, but sparse coverage makes the Q3 2024 figure unreliable for trend inference.

⚠ Nearly all ratio fields remain missing across the table — data gaps prevent any credible assessment of operational or financial trajectory.

⚠ ROE of -101.2% in Q3 2024 suggests equity is being rapidly eroded; burn rate and cash runway are critical metrics to track.

Get alerted when SRZN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Surrozen, Inc./DE including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SRZN

Column Group LLC
$55.8M1,916,950 sh
TCG Crossover Management, LLC
$42.9M1,473,101 sh
Boxer Capital Management, LLC
$22.3M766,318 sh
MILLENNIUM MANAGEMENT LLC
$21.3M731,138 sh
VR Adviser, LLC
$18.4M632,931 sh
Spruce Street Capital LP
$12.6M432,040 sh
BRAIDWELL LP
$11.5M396,100 sh
5AM Venture Management, LLC
$11.3M387,500 sh
Kalehua Capital Management LLC
$11.2M385,178 sh
Vestal Point Capital, LP
$9.9M338,611 sh

Fund	Value	Shares
Column Group LLC	$55.8M	1,916,950
TCG Crossover Management, LLC	$42.9M	1,473,101
Boxer Capital Management, LLC	$22.3M	766,318
MILLENNIUM MANAGEMENT LLC	$21.3M	731,138
VR Adviser, LLC	$18.4M	632,931
Spruce Street Capital LP	$12.6M	432,040
BRAIDWELL LP	$11.5M	396,100
5AM Venture Management, LLC	$11.3M	387,500
Kalehua Capital Management LLC	$11.2M	385,178
Vestal Point Capital, LP	$9.9M	338,611

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SRZN on your watchlist

Track score changes the day Surrozen, Inc./DE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SRZN a good stock to buy?

13F Pro's AI-powered analysis of Surrozen, Inc./DE (SRZN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SRZN are available on the SRZN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SRZN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SRZN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Surrozen, Inc./DE's investment landscape.